Bavarian Nordic A/S
BAVA.CODrugs in Pipeline
33
Phase 3 Programs
14
Upcoming Catalysts
2
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
IMVAMUNE®
Smallpox
FD MVA-BN
Smallpox
CHIKV VLP vaccine booster
Chikungunya Virus Infection
PXVX0200
Cholera
CHIKV VLP vaccine
Chikungunya Virus
PXVX0200 Lot A
Cholera
PROSTVAC-V
Prostate Cancer Metastatic
CHIKV VLP/adjuvant
Chikungunya Virus
MVA BN®
18-42 Year Old Healthy Vaccinia-naïve Subjects
ABNCoV2
COVID-19 Disease
SMC021 Oral calcitonin
Osteoporosis
JYNNEOS (Liquid Formulation)
Monkeypox Virus Infection
MVA-BN half-dose regimen
Mpox (Monkeypox)
MVA-BN standard regimen
Neonate
CHIKV VLP, adjuvanted
Chikungunya Virus
PROSTVAC®-VF/TRICOM™
Prostate Cancer
LF formulation of IMVAMUNE®
Smallpox
MVA-BN® (IMVAMUNE)
Smallpox
Chikungunya
Chikungunya
IMVAMUNE (MVA-BN)
Smallpox
MVA-BN
Monkeypox (Mpox)
BN-Brachyury plus radiation
Chordoma
CHIKV VLP/unadjuvanted
Chikungunya Virus Infection
CV301
Bladder Cancer
MVA-BN-WEV
Encephalitis
MVA-mBN85B
Measles
MVA-nef
HIV Infection
MVA-BN-RSV
Respiratory Syncytial Virus Infections
IMVAMUNE
Smallpox
MVA-mBN294B
RSV Infection
MVA-mBN32
HIV Infections
Jynneos
Monkeypox (Mpox)
ABNCoV2 100ug
COVID-19 Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMVAMUNE® | Phase 3 | Smallpox | - | - |
FD MVA-BN | Phase 3 | Smallpox | - | - |
CHIKV VLP vaccine booster | Phase 3 | Chikungunya Virus Infection | - | - |
PXVX0200 | Phase 3 | Cholera | - | - |
CHIKV VLP vaccine | Phase 3 | Chikungunya Virus | - | - |
PXVX0200 Lot A | Phase 3 | Cholera | - | - |
PROSTVAC-V | Phase 3 | Prostate Cancer Metastatic | - | - |
CHIKV VLP/adjuvant | Phase 3 | Chikungunya Virus | - | - |
MVA BN® | Phase 3 | 18-42 Year Old Healthy Vaccinia-naïve Subjects | - | - |
ABNCoV2 | Phase 3 | COVID-19 Disease | - | - |
SMC021 Oral calcitonin | Phase 3 | Osteoporosis | - | - |
JYNNEOS (Liquid Formulation) | Phase 3 | Monkeypox Virus Infection | - | - |
MVA-BN half-dose regimen | Phase 3 | Mpox (Monkeypox) | - | - |
MVA-BN standard regimen | Phase 3 | Neonate | - | - |
CHIKV VLP, adjuvanted | Phase 2 | Chikungunya Virus | - | - |
PROSTVAC®-VF/TRICOM™ | Phase 2 | Prostate Cancer | - | - |
LF formulation of IMVAMUNE® | Phase 2 | Smallpox | - | - |
MVA-BN® (IMVAMUNE) | Phase 2 | Smallpox | - | - |
Chikungunya | Phase 2 | Chikungunya | - | - |
IMVAMUNE (MVA-BN) | Phase 2 | Smallpox | - | - |
MVA-BN | Phase 2 | Monkeypox (Mpox) | - | - |
BN-Brachyury plus radiation | Phase 2 | Chordoma | - | - |
CHIKV VLP/unadjuvanted | Phase 2 | Chikungunya Virus Infection | - | - |
CV301 | Phase 2 | Bladder Cancer | - | - |
MVA-BN-WEV | Phase 2 | Encephalitis | - | - |
MVA-mBN85B | Phase 2 | Measles | - | - |
MVA-nef | Phase 2 | HIV Infection | - | - |
MVA-BN-RSV | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
IMVAMUNE | Phase 2 | Smallpox | - | - |
MVA-mBN294B | Phase 2 | RSV Infection | - | - |
MVA-mBN32 | Phase 2 | HIV Infections | - | - |
Jynneos | Phase 2 | Monkeypox (Mpox) | - | - |
ABNCoV2 100ug | Phase 2 | COVID-19 Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bavarian Nordic A/S's drug pipeline?→
CatalystAlert tracks 33 drug candidates in Bavarian Nordic A/S's (BAVA.CO) pipeline across Phase 3, Phase 2. Its lead program is IMVAMUNE® (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bavarian Nordic A/S's next FDA catalyst?→
Bavarian Nordic A/S's (BAVA.CO) next tracked catalyst is a Phase 2 expected November 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BAVA.CO biotech catalysts?→
Add BAVA.CO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bavarian Nordic A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.